Prompt injection in biotech and genomics AI

Four adversarial injection surfaces in biotech and genomics AI

1. NGS genomic sequencing result image injection (Benchling AI, Tempus AI, Foundation Medicine AI, 10x Genomics Xenium AI)

NGS genomic sequencing result AI processes next-generation sequencing quality display visualisation images, variant call format (VCF) quality metric display screenshots, genomic variant annotation and classification report display images, copy number variation (CNV) and structural variant (SV) visualisation images, RNA expression heatmap and differential expression analysis display images, single-cell transcriptomics UMAP and dimensionality reduction plot images, spatial transcriptomics tissue section gene expression overlay images, and chromosomal instability and mutational signature display images from Benchling AI serving more than 200,000 scientists at Moderna, Regeneron, BioNTech, and leading biotechnology companies through an enterprise life sciences R&D cloud platform processing experimental data and scientific image inputs through AI-assisted biological data extraction tools; Tempus AI integrating clinical and molecular data at 200+ health system partners processing genomic sequencing result and pathology evidence images through AI-assisted genomic variant classification and clinical data analysis pipelines for oncology treatment decision support; Foundation Medicine AI delivering comprehensive genomic profiling (CGP) for 500,000+ cancer patients through tissue and liquid biopsy AI-assisted next-generation sequencing with reporting used in oncology companion diagnostic and treatment selection decisions for FDA-approved targeted therapies; and 10x Genomics Xenium AI processing single-cell RNA sequencing, ATAC-seq, and spatial transcriptomics data visualisation images at pharmaceutical and academic research operations serving thousands of research institutions and drug developers through AI-assisted cell type classification and gene expression spatial pattern analysis tools — extracting genomic variant classifications and molecular biomarker determinations from next-generation sequencing result visualisation image inputs in AI-assisted clinical genomic diagnostic and drug discovery pipelines at genomic data volumes that make individual human genomicist review of every AI-processed sequencing result visualisation impracticable for large clinical genomic laboratory and biotechnology research operations.

The adversarial injection surface is the next-generation sequencing quality display, variant call visualisation, or genomic biomarker report display image submission pathway: Benchling AI or Tempus AI NGS result display images submitted through AI-assisted genomic variant classification and molecular biomarker identification tools for AI clinical genomic diagnostic record generation and oncology treatment recommendation input. An adversarially crafted NGS quality display or variant call visualisation — in which pixel perturbations applied to the variant allele frequency (VAF) indicator display region, the pathogenic variant classification visual marker, or the copy number amplification or deletion signal display in a genomic sequencing result image cause the AI to suppress a pathogenic variant indicator or tumour biomarker signal that would otherwise generate a clinical genomic report entry, a companion diagnostic eligibility determination, and an oncology treatment selection record — can create a clinical genomic AI record that fails to identify a clinically actionable pathogenic variant or therapeutic target biomarker that the actual sequencing data documents. In clinical genomic laboratory operations where Tempus AI or Foundation Medicine AI processes thousands of NGS result visualisation images per day without individual human genomicist pixel-level examination of every AI-processed sequencing display before the AI variant classification governs the clinical genomic report and oncology treatment recommendation, adversarial suppression of pathogenic variant indicators creates CLIA laboratory result accuracy, CAP accreditation, and FDA LDT guidance dimensions.

The CLIA, CAP, FDA LDT, and HIPAA consequences of adversarially suppressed genomic variant classification in NGS sequencing result AI span CLIA 42 USC §263a clinical laboratory improvement amendments certification requirements for laboratory test accuracy and result reliability applicable to clinical genomic diagnostic laboratories performing next-generation sequencing, College of American Pathologists (CAP) accreditation programme laboratory quality standards including CAP checklist requirements for NGS validation, quality metrics monitoring, and variant classification accuracy in molecular pathology and genomics laboratories, FDA laboratory developed test (LDT) Final Rule (effective May 2024, phased enforcement) requirements for analytical and clinical validation of laboratory developed genomic sequencing tests under 21 CFR Part 809, and HIPAA 45 CFR §164 protected health information privacy and security obligations applicable to clinical genomic laboratory result accuracy in systems processing patient-linked genomic data. CLIA 42 USC §263a requires clinical laboratories to enrol in proficiency testing programmes, maintain quality control procedures, and ensure the accuracy and reliability of clinical test results; adversarial manipulation of Tempus AI or Foundation Medicine AI NGS result visualisation classification that suppresses a pathogenic variant indicator creates CLIA laboratory test result accuracy obligation dimensions when the AI classification governs a clinical genomic report used in oncology treatment decisions. The FDA LDT Final Rule issued in May 2024 (21 CFR Part 809) subjects laboratory developed tests including NGS-based genomic profiling tests to FDA device regulatory requirements phased over four years; adversarially corrupted AI NGS variant classification creates FDA LDT analytical and clinical validity documentation accuracy obligations under the phased enforcement timeline. Threshold: 55 for NGS genomic sequencing result AI — reflecting CLIA 42 USC §263a laboratory accuracy, CAP accreditation NGS quality standards, FDA LDT Final Rule analytical validity, and HIPAA PHI accuracy dimensions.

2. Preclinical histopathology AI injection (preclinical safety study tissue slide AI)

Preclinical histopathology AI processes haematoxylin and eosin (H&E) stained tissue section microscopy images, immunohistochemistry (IHC) tissue marker staining display images, Ki-67 proliferation index and tumour grading tissue section photographs, TUNEL apoptosis and necrosis staining display images, organ histopathology peer review report display images, carcinogenicity bioassay tissue section classification images, and genotoxicity comet assay DNA damage display images from preclinical contract research organisations (CROs) including Charles River Laboratories AI, Covance (Labcorp) AI, and ICON plc AI at preclinical safety study operations serving pharmaceutical and biotechnology IND sponsors processing rodent and non-rodent species organ histopathology tissue section images through AI-assisted lesion identification and morphological severity grading tools; Recursion Pharmaceuticals AI at drug discovery safety profiling operations processing high-content cell imaging and biological assay tissue images through AI-assisted phenotypic toxicity signature classification tools; and pathology image analysis platforms including Paige AI, PathAI, Proscia AI, and Visiopharm AI at preclinical and translational pathology operations at major pharmaceutical companies processing H&E and IHC tissue section images through AI-assisted histopathological lesion classification and morphological severity assessment tools — extracting preclinical lesion severity classifications and carcinogenicity and genotoxicity signal determinations from histopathology tissue section image inputs in AI-assisted IND/NDA GLP toxicology study data generation pipelines at preclinical study tissue sample volumes that make individual human study pathologist pixel-level examination of every AI-processed tissue section image impracticable for large-scale multi-dose carcinogenicity bioassay operations.

The adversarial injection surface is the H&E tissue section microscopy image or IHC staining display image submission pathway: preclinical pathology AI or Recursion Pharmaceuticals AI histopathology tissue section images submitted through AI-assisted lesion identification and morphological severity grading tools for AI GLP preclinical study histopathology record generation and IND safety submission input. An adversarially crafted H&E tissue section image — in which pixel perturbations applied to the hepatocellular carcinoma or adenoma lesion display region, the renal tubular cell neoplasm morphological severity visual marker, or the bone marrow suppression cellularity indicator display in a preclinical organ histopathology image cause the AI to classify a tissue section documenting a treatment-related neoplastic or non-neoplastic lesion as a normal tissue section not meeting histopathological finding criteria when the actual stained tissue section evidences a drug-related adverse histopathological finding with ICH S1 carcinogenicity assessment significance — can suppress a histopathological finding that would otherwise generate a dose-response carcinogenicity determination, a no-observed-adverse-effect level (NOAEL) revision, and an IND safety reporting or NDA pharmacology/toxicology section data entry. In pharmaceutical IND programme operations where preclinical pathology AI processes hundreds of rodent carcinogenicity bioassay tissue section images per study without individual human peer-review pathologist examination of every AI-processed tissue section image before the AI lesion classification governs the GLP study histopathological findings table and IND/NDA regulatory submission, adversarial suppression of preclinical neoplastic lesion indicators creates GLP 21 CFR Part 58 study data integrity and IND/NDA submission accuracy dimensions.

The GLP 21 CFR Part 58, ICH S1/S2, FDA 21 CFR Part 312/314, and 18 USC §1001 consequences of adversarially suppressed histopathological finding classification in preclinical histopathology AI span FDA 21 CFR Part 58 Good Laboratory Practice regulations for non-clinical laboratory studies requiring accurate and auditable study data generation, ICH S1A/S1B carcinogenicity study guidance and ICH S2(R1) genotoxicity study guidance applicable to IND-supporting preclinical safety package composition and carcinogenicity bioassay histopathological evaluation standards, FDA 21 CFR Part 312 IND safety reporting obligations including immediate safety reporting requirements for unexpected serious adverse drug reactions discovered in preclinical study re-evaluation, FDA 21 CFR Part 314 NDA pharmacology/toxicology section submission accuracy requirements for complete carcinogenicity study reports, and 18 USC §1001 false statements to federal agencies applicable to preclinical study data falsification in IND/NDA submissions. FDA 21 CFR Part 58 requires that non-clinical laboratory studies intended to support IND or NDA submissions be conducted under GLP conditions including accurate, contemporaneous, and auditable raw data generation; adversarial manipulation of preclinical pathology AI that suppresses histopathological lesion findings creates GLP 21 CFR §58.130 data recording and §58.63 quality assurance unit audit trail accuracy dimensions when adversarially corrupted AI histopathology classifications constitute the raw data supporting GLP study histopathological findings tables. ICH S1B requires that rodent carcinogenicity bioassays submitted in support of IND/NDA submissions include complete histopathological examination of at least 40 tissues per animal in all dose groups; adversarially suppressed neoplastic lesion indicators in AI histopathology classification create ICH S1B histopathological examination completeness and dose-response characterisation accuracy dimensions. 18 USC §1001 makes it a federal crime to knowingly make any materially false, fictitious, or fraudulent statement or representation in any matter within the jurisdiction of the executive branch; IND/NDA submissions to FDA are within federal jurisdiction under 18 USC §1001, and preclinical histopathology AI classifications that adversarially suppress GLP study carcinogenicity findings submitted in IND safety updates or NDA pharmacology/toxicology sections create 18 USC §1001 false statements exposure. Threshold: 55 for preclinical histopathology AI — reflecting GLP 21 CFR Part 58 data integrity, ICH S1/S2 carcinogenicity/genotoxicity assessment accuracy, FDA 21 CFR Part 312/314 IND/NDA submission accuracy, and 18 USC §1001 false statements dimensions.

3. Drug discovery compound activity image injection (Recursion Pharmaceuticals AI, Schrödinger AI, Insilico Medicine AI)

Drug discovery compound activity AI processes high-content cell imaging assay result images, dose-response curve and IC50/EC50 visualisation display images, cell viability and cytotoxicity assay result images, phenotypic screening hit compound activity heatmap images, molecular dynamics simulation trajectory display images, protein-ligand docking pose and binding affinity visualisation images, and target engagement and occupancy assay result display images from Recursion Pharmaceuticals AI at computational drug discovery operations processing 1.4 petabytes of biological image data through AI-assisted phenotypic compound activity classification and drug target identification tools; Schrödinger AI at computational chemistry drug discovery operations serving 1,700+ pharmaceutical company clients through AI-assisted free energy perturbation binding affinity prediction and protein structure-activity relationship modelling tools; Insilico Medicine AI at generative chemistry drug discovery operations processing compound screening assay result images through AI-assisted target identification and drug candidate activity classification tools; and Relay Therapeutics AI, Exscientia AI, and BioNTech AI at AI-first drug discovery company operations processing compound phenotypic screening and molecular simulation result images through AI-assisted compound activity classification and lead optimisation decision support tools — extracting compound activity classifications and drug discovery hit and lead identification determinations from high-content cell imaging assay result and molecular simulation display image inputs in AI-assisted drug discovery candidate prioritisation pipelines at compound screening library volumes that make individual human medicinal chemist review of every AI-processed assay result image impracticable for large AI-first drug discovery operations.

The adversarial injection surface is the high-content cell imaging assay result image or dose-response curve visualisation display image submission pathway: Recursion Pharmaceuticals AI or Schrödinger AI compound activity classification images submitted through AI-assisted phenotypic screening hit identification and lead compound prioritisation tools for AI drug discovery programme decision record generation and regulatory development candidate selection input. An adversarially crafted high-content cell imaging assay result image — in which pixel perturbations applied to the cell viability and cytotoxicity indicator display region, the compound activity Z-prime and signal-to-noise quality metric visual marker, or the dose-response inflection and IC50 determination display in a compound screening assay result image cause the AI to suppress a compound cytotoxicity or off-target activity indicator that would otherwise generate a compound safety flag, a lead compound exclusion determination, and a drug discovery safety triage record — can create an AI compound activity classification record that advances a cytotoxic or safety-flagged compound into lead optimisation or development candidate nomination stages with IND-enabling GLP toxicology study and clinical trial safety consequences. In AI-first drug discovery operations where Recursion AI or Schrödinger AI processes millions of compound assay result images per screening campaign without individual human medicinal chemist cytotoxicity pixel-level examination of every AI-processed screening result before the AI activity classification governs the compound prioritisation and lead optimisation programme decision, adversarial suppression of cytotoxicity and off-target activity indicators creates FDA 21 CFR Part 312 IND safety reporting and ICH S1/S2 preclinical safety package composition dimensions.

The ICH S1/S2, FDA 21 CFR Part 312, FDA 21 CFR Part 314, and GLP consequences of adversarially suppressed compound cytotoxicity classification in drug discovery AI span ICH S1A/S1B carcinogenicity study design guidance applicable to the selection of doses and species for IND-enabling carcinogenicity studies informed by drug discovery compound activity and safety profiling classifications, ICH S2(R1) genotoxicity testing guidance applicable to the design of the IND-enabling genotoxicity battery based on discovery-stage compound mechanism-of-action and structural alert classifications, FDA 21 CFR Part 312 IND application requirements for pharmacology/toxicology sections including a summary of the results of all non-clinical pharmacology, toxicology, and pharmacokinetic studies with the investigational drug, and FDA 21 CFR Part 314 NDA pharmacology/toxicology requirements for complete study reports in the integrated summary of safety. ICH M7(R2) assessment and control of DNA reactive impurities in pharmaceuticals requires that manufacturing process impurities and drug product metabolites be evaluated for DNA reactivity and mutagenic potential; adversarially suppressed genotoxicity signal indicators in drug discovery AI compound activity classifications create ICH M7(R2) mutagenic impurity assessment accuracy dimensions when AI-assisted compound activity screening results govern the ICH M7(R2) acceptable intake limit determinations for clinical safety monitoring. FDA Guidance for Industry on drug interaction studies (FDA-2020-D-1717) requires that drug metabolism and transporter interaction liabilities identified in discovery-stage compound screening inform clinical study design and drug-drug interaction study protocols; adversarially suppressed metabolic enzyme inhibition and transporter activity indicators in AI compound screening classifications create FDA drug interaction guidance clinical study design accuracy dimensions. Threshold: 60 for drug discovery compound activity AI — reflecting ICH S1/S2 preclinical safety assessment accuracy, FDA 21 CFR Part 312 IND pharmacology/toxicology summary accuracy, ICH M7(R2) mutagenic impurity assessment, and FDA drug interaction guidance discovery-to-clinical translation dimensions.

4. CMC pharmaceutical manufacturing QC image injection (21 CFR Part 211 cGMP AI)

CMC pharmaceutical manufacturing QC AI processes batch manufacturing record document photograph images, raw material certificate of analysis (CoA) document scan images, in-process control (IPC) and finished product QC analytical data display images, dissolution profile and content uniformity display images, sterility testing and environmental monitoring plate count result photographs, visual inspection and particulate matter screening image captures, packaging line label verification and coding display images, and stability study time-point analytical result display images from pharmaceutical manufacturing operations at major contract development and manufacturing organisations (CDMOs) including Lonza AI, Catalent AI, Samsung Biologics AI, and Boehringer Ingelheim Biopharmaceuticals AI processing batch record and QC documentation images through AI-assisted cGMP manufacturing data extraction and out-of-specification result identification tools; pharmaceutical company quality assurance operations at Pfizer, Merck, AstraZeneca, and Johnson & Johnson manufacturing sites processing batch record and laboratory analytical result images through AI-assisted QC data review and batch release determination tools; and pharmaceutical manufacturing AI platform vendors including Apprentice.io AI, Plex DEM AI, and Tetra Data AI (LabVantage) at cGMP pharmaceutical manufacturing quality management system operations processing manufacturing batch record and QC analytical data images through AI-assisted deviation detection and batch disposition classification tools — extracting cGMP manufacturing compliance classifications and OOS result identifications from batch record document photograph and QC analytical data display image inputs in AI-assisted pharmaceutical batch release and regulatory filing data generation pipelines at manufacturing documentation volumes that make individual human quality assurance reviewer examination of every AI-processed batch record photograph impracticable for large-scale CDMO and integrated pharmaceutical manufacturing operations.

The adversarial injection surface is the batch manufacturing record photograph or QC analytical result display image submission pathway: Lonza AI or Catalent AI cGMP manufacturing QC documentation photograph images submitted through AI-assisted batch record review and out-of-specification result identification tools for AI pharmaceutical batch release determination generation and regulatory manufacturing data record input. An adversarially crafted batch manufacturing record photograph or QC analytical result display image — in which pixel perturbations applied to the out-of-specification assay result value display region, the dissolution specification non-conformance indicator visual marker, or the environmental monitoring exceedance alert display in a pharmaceutical manufacturing QC document image cause the AI to classify a batch record documenting an OOS analytical result or a cGMP deviation as a conforming batch record not meeting investigation-triggering criteria when the actual manufacturing document evidences an OOS result requiring a 21 CFR §211.192 out-of-specification investigation and potential batch rejection or recall determination — can suppress an OOS result indicator that would otherwise generate a batch rejection investigation record, a regulatory authority notification, and a pharmaceutical product quality regulatory compliance record. In cGMP pharmaceutical manufacturing operations where Lonza AI or Catalent AI processes hundreds of batch record and QC analytical result document photographs per batch without individual human QA pharmacist pixel-level examination of every AI-processed manufacturing document before the AI cGMP classification governs the batch disposition and release determination, adversarial suppression of OOS result indicators creates FDA 21 CFR Part 211 cGMP OOS investigation obligation and pharmaceutical product quality regulatory compliance dimensions.

The FDA 21 CFR Part 211 cGMP, FDA consent decree, ICH Q7, and 21 USC §331 consequences of adversarially suppressed OOS result classification in cGMP pharmaceutical manufacturing QC AI span FDA 21 CFR Part 211 current good manufacturing practice regulations for finished pharmaceuticals including 21 CFR §211.192 OOS investigation obligation requirements, 21 CFR §211.68 computerised system and data integrity requirements, and 21 CFR §211.194 laboratory record completeness requirements for all raw data generated during laboratory test performance; FDA consent decree authority under 21 USC §332 injunctive relief applicable to pharmaceutical manufacturers with repeated cGMP violations including data integrity failures at AI-assisted manufacturing quality systems; ICH Q7 good manufacturing practice guidance for active pharmaceutical ingredients requiring data integrity, audit trail completeness, and OOS investigation procedure compliance for API manufacturing operations; FDA Guidance for Industry on Investigating OOS Test Results for Pharmaceutical Production (2006) requiring thorough OOS investigation procedures including Phase I laboratory investigation and Phase II manufacturing investigation for any analytical result outside established acceptance criteria; and 21 USC §331 prohibited acts making it unlawful to introduce into interstate commerce any adulterated or misbranded drug, with adulteration defined under 21 USC §351 to include manufacturing under conditions that do not conform to current good manufacturing practice. FDA 21 CFR §211.192 requires that any unexplained discrepancy, including a failure of a batch to meet any specification, be investigated thoroughly; adversarial manipulation of pharmaceutical manufacturing QC AI that suppresses OOS result indicators creates §211.192 OOS investigation obligation failures with FDA Warning Letter, Form 483 inspection observation, and consent decree exposure when OOS investigation failures affect marketed pharmaceutical products. FDA data integrity guidance (2018) requires that all computerised systems used in GMP-regulated pharmaceutical manufacturing maintain attributable, legible, contemporaneous, original, and accurate (ALCOA+) data records; adversarially corrupted AI QC image classifications that suppress OOS result indicators create FDA data integrity ALCOA+ accuracy documentation failures. Threshold: 65 for CMC pharmaceutical manufacturing QC AI — reflecting FDA 21 CFR Part 211 cGMP OOS investigation obligations, FDA consent decree authority, ICH Q7 API GMP data integrity, FDA data integrity ALCOA+ requirements, and 21 USC §331 adulterated pharmaceutical product interstate commerce dimensions.

Integration: biotech and genomics AI image ingestion with Glyphward pre-scan

Biotech and genomics AI image ingestion flows from Benchling AI and Tempus AI NGS genomic sequencing result and variant call visualisation channels, preclinical pathology AI H&E tissue section and IHC staining image interfaces, Recursion Pharmaceuticals AI and Schrödinger AI drug discovery compound activity assay result image platforms, and Lonza AI and Catalent AI cGMP pharmaceutical manufacturing QC batch record photograph processing systems into genomic variant classification AI, preclinical lesion identification and severity grading AI, compound activity and cytotoxicity classification AI, and pharmaceutical batch release OOS result identification AI pipelines. Insert Glyphward’s pre-scan at the ingestion boundary before AI-generated output is committed to clinical genomic diagnostic reports, GLP preclinical study histopathological findings tables, drug discovery compound prioritisation records, or cGMP pharmaceutical batch release determinations:

import asyncio
import base64
import hashlib
import os
import uuid
from enum import Enum
from pathlib import Path

import httpx

GLYPHWARD_API_KEY = os.environ["GLYPHWARD_API_KEY"]
GLYPHWARD_SCAN_URL = "https://glyphward.com/v1/scan"

# Biotech & genomics AI — CLIA 42 USC §263a; CAP accreditation; FDA LDT Final Rule;
# HIPAA 45 CFR §164; GLP 21 CFR Part 58; ICH S1/S2; FDA 21 CFR Part 312/314;
# FDA 21 CFR Part 211 cGMP §211.192 OOS; 18 USC §1001 false statements.
THRESHOLD_NGS_GENOMIC_SEQUENCING_AI      = 55  # Benchling/Tempus; CLIA; CAP; FDA LDT
THRESHOLD_PRECLINICAL_HISTOPATHOLOGY_AI  = 55  # CRO/Recursion; GLP 21 CFR Part 58; ICH S1
THRESHOLD_DRUG_DISCOVERY_COMPOUND_AI     = 60  # Recursion/Schrodinger; ICH M7; FDA 21 CFR 312
THRESHOLD_CMC_MANUFACTURING_QC_AI        = 65  # Lonza/Catalent; 21 CFR §211.192; ICH Q7


class BiotechGenomicsAIContext(str, Enum):
    NGS_GENOMIC_SEQUENCING_AI      = "ngs_genomic_sequencing_ai"     # Benchling, Tempus, Foundation Medicine
    PRECLINICAL_HISTOPATHOLOGY_AI  = "preclinical_histopathology_ai" # Charles River, Covance, Recursion
    DRUG_DISCOVERY_COMPOUND_AI     = "drug_discovery_compound_ai"    # Recursion, Schrodinger, Insilico
    CMC_MANUFACTURING_QC_AI        = "cmc_manufacturing_qc_ai"       # Lonza, Catalent, Samsung Biologics


def threshold_for(context: BiotechGenomicsAIContext) -> int:
    mapping = {
        BiotechGenomicsAIContext.NGS_GENOMIC_SEQUENCING_AI:      THRESHOLD_NGS_GENOMIC_SEQUENCING_AI,
        BiotechGenomicsAIContext.PRECLINICAL_HISTOPATHOLOGY_AI:  THRESHOLD_PRECLINICAL_HISTOPATHOLOGY_AI,
        BiotechGenomicsAIContext.DRUG_DISCOVERY_COMPOUND_AI:     THRESHOLD_DRUG_DISCOVERY_COMPOUND_AI,
        BiotechGenomicsAIContext.CMC_MANUFACTURING_QC_AI:        THRESHOLD_CMC_MANUFACTURING_QC_AI,
    }
    return mapping[context]


async def scan_biotech_genomics_ai_image(
    image_path: str | Path,
    context: BiotechGenomicsAIContext,
    study_entity_hash: str,    # SHA-256 of patient MRN, study animal ID, lot number, or compound ID
    protocol_ref: str,         # e.g. "NGS-TMP-2026-88421", "GLP-CRL-TOX-2026-331", "LOT-2026-44812"
    analysis_session_id: str,  # sequencing run ID, study path. report ID, or batch record ID
    client: httpx.AsyncClient,
) -> dict:
    """
    Scan a biotech or genomics AI image for adversarial injection payloads
    before forwarding to NGS genomic variant classification, preclinical tissue
    histopathology lesion identification, drug discovery compound activity assessment,
    or CMC pharmaceutical manufacturing QC OOS result identification AI systems.

    Raises AdversarialBiotechGenomicsAIImageError if score meets threshold:
      - NGS_GENOMIC_SEQUENCING_AI:      threshold 55; CLIA §263a; CAP; FDA LDT Final Rule
      - PRECLINICAL_HISTOPATHOLOGY_AI:  threshold 55; GLP 21 CFR Part 58; ICH S1/S2
      - DRUG_DISCOVERY_COMPOUND_AI:     threshold 60; ICH M7(R2); FDA 21 CFR Part 312
      - CMC_MANUFACTURING_QC_AI:        threshold 65; 21 CFR §211.192 OOS; ICH Q7
    """
    image_bytes     = Path(image_path).read_bytes()
    image_b64       = base64.b64encode(image_bytes).decode()
    image_sha256    = hashlib.sha256(image_bytes).hexdigest()
    client_scan_id  = str(uuid.uuid4())
    threshold       = threshold_for(context)

    resp = await client.post(
        GLYPHWARD_SCAN_URL,
        headers={"Authorization": f"Bearer {GLYPHWARD_API_KEY}"},
        json={
            "image": image_b64,
            "source": context.value,
            "metadata": {
                "biotech_genomics_context": context.value,
                "study_entity_hash":        study_entity_hash,
                "protocol_ref":             protocol_ref,
                "analysis_session_id":      analysis_session_id,
                "client_scan_id":           client_scan_id,
                "image_sha256":             image_sha256,
            },
        },
        timeout=8.0,
    )
    resp.raise_for_status()
    result = resp.json()

    audit_record = {
        "study_entity_hash":       study_entity_hash,
        "protocol_ref":            protocol_ref,
        "analysis_session_id":     analysis_session_id,
        "biotech_genomics_context": context.value,
        "scan_id":                 result["scan_id"],
        "client_scan_id":          client_scan_id,
        "image_sha256":            image_sha256,
        "score":                   result["score"],
        "flagged_region":          result.get("flagged_region"),
        "threshold":               threshold,
        "action":                  "blocked" if result["score"] >= threshold else "allowed",
    }
    await write_biotech_audit_record(audit_record)

    if result["score"] >= threshold:
        raise AdversarialBiotechGenomicsAIImageError(
            f"Biotech genomics AI image blocked [{context.value}]: "
            f"scan_id={result['scan_id']} score={result['score']} "
            f"entity={study_entity_hash} protocol={protocol_ref}"
        )
    return result


async def write_biotech_audit_record(record: dict) -> None:
    """Persist audit record to biotech and genomics regulatory compliance documentation store (stub)."""
    import json, sys
    print(json.dumps(record), file=sys.stderr)


class AdversarialBiotechGenomicsAIImageError(Exception):
    """Raised when a biotech or genomics AI image exceeds the adversarial injection threshold."""
    pass

Call scan_biotech_genomics_ai_image() with BiotechGenomicsAIContext.NGS_GENOMIC_SEQUENCING_AI before forwarding Benchling AI, Tempus AI, or Foundation Medicine AI next-generation sequencing quality display and genomic variant call visualisation images to AI-assisted variant classification and molecular diagnostic report generation systems — with protocol_ref linking the Glyphward scan to the clinical genomic test order for CLIA 42 USC §263a laboratory accuracy, CAP accreditation NGS validation, and FDA LDT Final Rule analytical validity compliance documentation. Call with BiotechGenomicsAIContext.PRECLINICAL_HISTOPATHOLOGY_AI for Charles River Laboratories, Covance, or ICON H&E tissue section and IHC staining display images before preclinical lesion identification and morphological severity grading AI systems — with study_entity_hash as the SHA-256 of the GLP study animal identifier for GLP 21 CFR Part 58 data integrity, ICH S1/S2 carcinogenicity and genotoxicity assessment accuracy, and 18 USC §1001 false statements IND/NDA submission audit trail documentation. Call with BiotechGenomicsAIContext.DRUG_DISCOVERY_COMPOUND_AI for Recursion Pharmaceuticals AI, Schrödinger AI, or Insilico Medicine AI compound activity assay result and dose-response curve display images before compound activity classification and lead prioritisation AI, with protocol_ref as the compound screening campaign identifier for ICH M7(R2) mutagenic impurity assessment accuracy, ICH S1/S2 preclinical safety package design, and FDA 21 CFR Part 312 IND pharmacology/toxicology summary accuracy documentation. Call with BiotechGenomicsAIContext.CMC_MANUFACTURING_QC_AI for Lonza AI, Catalent AI, or Samsung Biologics AI batch manufacturing record photograph and QC analytical result display images before batch release OOS result identification AI — with analysis_session_id as the batch record number for FDA 21 CFR §211.192 OOS investigation obligation compliance, ICH Q7 API GMP data integrity, FDA data integrity ALCOA+ requirements, and 21 USC §331 adulterated pharmaceutical product interstate commerce audit trail. Get early access

Coverage matrix

Frequently asked questions

Further reading

• Pharmaceutical drug discovery AI prompt injection — related adversarial attack surface covering AI injection in drug discovery operations with FDA, ICH, and preclinical safety study dimensions applicable to biotech genomics AI contexts where computational chemistry and phenotypic screening result images intersect with regulatory submission requirements.
• Clinical trials and pharmaceutical AI prompt injection — related regulatory framework covering clinical trial evidence generation AI with FDA 21 CFR Part 312/314, ICH E6(R3) GCP, and FDA clinical trial data integrity dimensions applicable to biotech genomics AI where NGS genomic sequencing results and histopathology findings inform clinical trial endpoint determinations.
• Digital pathology and clinical laboratory AI prompt injection — related adversarial attack surface covering clinical diagnostic AI with CLIA, CAP, and FDA LDT dimensions directly applicable to biotech genomics AI contexts where computational pathology and genomic diagnostic testing converge in cancer genomics operations.
• Free tier — 10 scans/day, no card required — start scanning biotech and genomics AI images at development volumes before committing to a production plan.